Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Sihuan Pharmaceutical Holdings Group EV-to-EBITDA?
Sihuan Pharmaceutical Holdings GroupSHPHY 56 EV-to-EBITDA is 5.99 as of Aug. 16, 2026, which is 3% below its 10-year median of 6.15. GuruFocus rates SHPHY with a GF Score™ of 56/100 and a GF Value™ of $6.15 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 735 Drug Manufacturers companies, Sihuan Pharmaceutical Holdings Group ranks better than 82.18% on this metric.
SHPHY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.22 Med: 6.15 Max: 126.67
Current: 5.89
During the past 13 years, the highest EV-to-EBITDA of Sihuan Pharmaceutical Holdings Group was 126.67. The lowest was -4.22. And the median was 6.15.
SHPHY's EV-to-EBITDA is ranked better than 82.18% of 735
companies
in the Drug Manufacturers industry
Industry Median: 13.3
vs SHPHY: 5.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sihuan Pharmaceutical Holdings Group (OTCPK:SHPHY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sihuan Pharmaceutical Holdings Group's PE Ratio (TTM) for today is calculated as:
Sihuan Pharmaceutical Holdings Group's share price for today is $4.355.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sihuan Pharmaceutical Holdings Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.111.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group EV-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sihuan Pharmaceutical Holdings Group EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's EV-to-EBITDA falls into.
Sihuan Pharmaceutical Holdings Group's current Enterprise Value is $712.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sihuan Pharmaceutical Holdings Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $118.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sihuan Pharmaceutical Holdings Group (SHPHY) has a EV-to-EBITDA of 5.99 as of Aug. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sihuan Pharmaceutical Holdings Group. This is near median its historical median of 6.15. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #131 out of 735 companies in the Drug Manufacturers industry, placing it in the top 17.8%.
Is Sihuan Pharmaceutical Holdings Group's EV-to-EBITDA too high?
Sihuan Pharmaceutical Holdings Group's current EV-to-EBITDA of 5.99 is near median its 10-year median of 6.15. The Drug Manufacturers industry median EV-to-EBITDA is 13.30. Sihuan Pharmaceutical Holdings Group's value of 5.99 is 55% below this industry median. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #131 out of 735 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #131 out of 735 companies for EV-to-EBITDA. This places Sihuan Pharmaceutical Holdings Group in the top 18% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.30. Sihuan Pharmaceutical Holdings Group's value of 5.99 is 55% below this benchmark. While the company's 10-year median is 6.15 vs. the industry median of 13.30, Sihuan Pharmaceutical Holdings Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.30, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sihuan Pharmaceutical Holdings Group's current EV-to-EBITDA of 5.99 is 55% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sihuan Pharmaceutical Holdings Group. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sihuan Pharmaceutical Holdings Group's current EV-to-EBITDA is 5.99, which is near median its own 10-year median of 6.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHY) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.15, compared to a current price of $4.36 — trading 29.2% below its estimated fair value. The current EV-to-EBITDA is 5.99, which is near median its 10-year median of 6.15 and 55% below the Drug Manufacturers industry median of 13.30. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHY), the current EV-to-EBITDA is 5.99 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sihuan Pharmaceutical Holdings Group (SHPHY) Overvalued in 2026?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued.
The current stock price of $4.36 is trading 29.2% below its estimated GF Value™ of $6.15.
GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.
Key valuation signals for SHPHY:
EV-to-EBITDA: 5.99 (near median its 10-year median of 6.15)
GF Value™: $6.15 vs. price of $4.36 (29.2% below fair value)
Industry Position: 55% below the Drug Manufacturers median (#131 of 735)
No single metric tells the full story. See the SHPHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
56GF Score
Get the complete analysis for SHPHY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPHY has been successfully added to your 
